RESEARCH TRIANGLE PARK, N.C. — Adherex (AMEX: ADH), which is developing a variety of oncology drugs, reported in increase in losses for the third quarter on Monday as the company’s drugs advance further in clinical trials.

Losses increased to $5 million, or 10 cents per share, compared to $4.4 million for the same period in 2005. Operating expenses also increased to $5.3 million, up $500,000 over the previous year.